Eli Lilly announced positive results from its Phase 3b study of Ebglyss, which focused on patients with moderate-to-severe ...

Axicabtagene ciloleucel, known by the brand name Yescarta, has been accepted for treating adults with two types of blood cancer.

Probably the biggest objection to buying Lilly stock is its valuation. The big pharmaceutical company's shares trade at nearly 37.5 times forward earnings. Does this high multiple disqualify Lilly as ...

Ladies and gentlemen, thank you for standing-by, and welcome to the Lilly Q3 2024 Earnings Call. [Operator Instructions] I ...

The company’s new products, including Ebglyss and Kisunla, reported a revenue increase of $3.07 billion, reaching $4.51 billion in Q3 2024. Mounjaro alone generated $3.11 billion in revenue, ...

Approvals included Ebglyss in the U.S. for moderate-to-severe atopic dermatitis and Kisunla in Japan for early symptomatic Alzheimer's disease. Positive Phase 3 data included the 176-week study of ...

The new product approvals for Ebglyss and Kisunla, exciting new pipeline data for tirzepatide, donanemab, imlunestrant and lebrikizumab, as well as key milestone achievements in our supply network, ...

The new product approvals for Ebglyss and Kisunla, exciting new pipeline data for tirzepatide, donanemab, imlunestrant and lebrikizumab, as well as key milestone achievements in our supply network ...

The ADapt study assessed the efficacy and safety of EBGLYSS in individuals who had previously been treated with dupilumab.

Eli Lilly's EBGLYSS has demonstrated improvement in skin condition and itch relief in patients with moderate-to-severe atopic dermatitis, according to new results from the Phase IIIb ADapt study.